Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

ORY | MC

Overview

Corporate Details

ISIN(s):
ES0167733015
LEI:
95980063R15RDF29DK13
Country:
Spain
Address:
Sant Ferran 74, 08940 Cornellà de Llobregat
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. The company discovers, develops, and plans to commercialize innovative, personalized medicines for diseases with high unmet medical needs. Utilizing its proprietary epigenetics platform, Oryzon focuses on two main therapeutic areas: oncology and central nervous system (CNS) disorders. The platform enables the identification and validation of biomarkers and therapeutic targets, translating them into advanced clinical programs.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oryzon Genomics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de A…
Spanish 44.3 KB
2025-05-26 08:04
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-26 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-12 07:52
Earnings Release
La sociedad remite información sobre los resultados del primer trimestre de 2025
Spanish 370.8 KB
2025-05-08 08:06
Regulatory News Service
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
Spanish 250.1 KB
2025-04-29 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-04-25 13:52
Declaration of Voting Results & Voting Rights Announcements
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
Spanish 202.4 KB
2025-04-24 08:13
Share Issue/Capital Change
Resultado de la colocación acelerada
Spanish 178.7 KB
2025-04-23 18:34
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-04-23 17:58
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-02-28 14:54
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 51.6 KB
2025-02-28 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 55.0 KB
2025-02-27 19:03
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 189.1 KB
2025-02-27 18:57
Governance Information
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 437.0 KB
2025-02-27 00:00
Annual Report
Spanish 13.7 MB

Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NextCell Pharma AB Logo
Develops MSC therapies for autoimmune diseases and offers private stem cell banking services.
Sweden NXTCL
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions for pharma licensing.
France ALNFL
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
Nortem BioGroup Logo
Biotech R&D of natural products for consumer health, home, and animal nutrition.
Spain MLBIO
NRGene Technologies Ltd. Logo
AI genomics software accelerating plant & animal breeding for the agriculture industry.
Israel NRGN
NUFORMIX PLC Logo
A pharma firm repurposing drugs for fibrosis and oncology via proprietary cocrystal technology.
United Kingdom NFX
Nykode Therapeutics ASA Logo
Developing targeted immunotherapies and vaccines for cancer and infectious diseases.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive drugs for sight-threatening eye diseases.
Switzerland OCS
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC